Cargando…
MON-LB008 PD-L1 Expression in Normal Endocrine Tissues
Introduction: Immune checkpoint inhibitor (ICI) therapy, including cytotoxic T-lymphocyte-associated protein 4 (CLTA-4) and programmed cell death 1 (PD-1) inhibitors, is revolutionizing cancer treatment. However, these agents are associated with immune-related adverse events (irAEs), most commonly e...
Autores principales: | Pollack, Rena, Kagan, Maayan, Dresner-Pollak, Rivka, Tzahi, Neuman |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Endocrine Society
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6550633/ http://dx.doi.org/10.1210/js.2019-MON-LB008 |
Ejemplares similares
-
MON-LB006 Glucocorticoid Biosynthetic Pathway Analysis Divulges the Susceptibility of Adrenal Gland against EDCs In Vivo by Novel Approach Uncovering Endocrine Disruption Mechanism
por: Ahmad, Shahzad, et al.
Publicado: (2019) -
MON-LB007 Incidence and Characteristics of Thyroid and Pituitary Dysfunction in Patients Treated with Immunotherapy
por: Casey, Caoimhe, et al.
Publicado: (2019) -
MON-LB009 Renin Angiotensin Aldosterone System Inactivation in Postural Orthostatic Tachycardia Syndrome
por: Kumar, Vishak, et al.
Publicado: (2019) -
MON-035 Aldosterone Secretion in a Human Adrenal Cell Line Is Enhanced by the Endocrine-Disrupting Chemical Di-(2-Ethylhexyl) Phthalate (DEHP)
por: Schupbach, Chad, et al.
Publicado: (2019) -
MON-033 Evaluating the Estrogen Activity of OTC Products Containing Parabens
por: Baer, Caroline, et al.
Publicado: (2019)